

In the Claims:

For the Examiner's convenience, Applicants present all pending claims with status indicators in compliance with the practice guidelines for making amendments under 37 C.F.R. §1.121(c)(1).

Please cancel claims 1-29 and 32. Additionally, please amend claims 30, 33-35 and add new claims 36-37 as follows:

Claims 1-29 CANCEL

30. (CURRENTLY AMENDED) A method of detecting a disease-state in a subject, wherein the disease-state is associated with expression of an RG1 polypeptide having the amino acid sequence of SEQ ID NO: 2, and wherein the method comprises:
- (a) administering to the subject an immunoconjugate ~~of Claim 22~~, wherein the immunoconjugate comprises an antibody or a fragment or a variant thereof that specifically binds to an epitope present in the RG1 polypeptide having the amino acid sequence of SEQ ID NO: 2 and wherein the antibody or the fragment or the variant thereof is conjugated to a molecule which is a detectable marker;
 - (b) detecting the ~~binding of the~~ immunoconjugate ~~within the subject~~; and
 - (c) determining if the level of binding of the immunoconjugate ~~in the subject~~ is increased as compared with the level of binding detected in disease-free control subjects, an increased level being indicative of a disease state.
31. (PREVIOUSLY PRESENTED) The method of Claim 30, wherein the method of detection is immunoscintigraphy.

32. (CANCEL)
33. (CURRENTLY AMENDED) The method of Claim ~~32~~ 30, wherein the method of detection is positron emitting tomography.
34. (CURRENTLY AMENDED) The method of Claim ~~33~~ 30, wherein the detectable marker of the immunoconjugate is selected from a group consisting of ^{43}Sc , ^{44}Sc , ^{52}Fe , ^{55}Co , ^{68}Ga , ^{64}Cu , ^{86}Y , ~~$^{94\text{m}}\text{Tc}$~~ , ^{111}In , or ^{90}Y .
35. (CURRENTLY AMENDED) The method of Claim ~~34~~ 30, wherein the disease-state is prostate cancer.
36. (NEW) The method of claim 30, wherein the detectable marker is a radioisotope, a fluorescent compound, a bioluminescent compound, chemiluminescent compound, a metal chelator or an enzyme.
37. (NEW) The method of claim 30, wherein the antibody is selected from a group consisting of a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a humanized antibody and a fully-human antibody.